Glioblastoma Targeted Treatment Option Maximization by Whole Genome Sequencing
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
In Dutch centers performing neurosurgery on and/or treating GBM, all recurrent GBM patients are discussed in local tumor boards and this setup will be used to effectively identify possible GLOW study candidates. 160 patients that will undergo re-resection in the GLOW study will be presented with WGS results leading to added treatment options.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histopathologically confirmed IDH wild type glioblastoma, first recurrence after standard chemoradiation; suitable for standard-of-care re-resection;
• Age ≥ 18 years;
• Able and willing to give written informed consent;
• Life expectancy \>3 months, allowing adequate follow-up of toxicity evaluation and antitumor activity;
• KPS performance status ≥70.
Locations
Other Locations
Netherlands
Haaglanden Medisch Centrum
RECRUITING
The Hague
Contact Information
Primary
Mark Y van Opijnen
m.van.opijnen@haaglandenmc.nl
0031-88-9797900
Backup
Marike Broekman
m.broekman@gmail.com
Time Frame
Start Date: 2022-07-25
Estimated Completion Date: 2025-07-01
Participants
Target number of participants: 160
Treatments
Experimental: whole genome sequencing after standard of care resection at first relapse
Related Therapeutic Areas
Sponsors
Collaborators: The Netherlands Cancer Institute, University Medical Center Groningen, Medisch Spectrum Twente, Radboud University Medical Center, Isala, Amsterdam University Medical Center, Maastricht University Medical Center, Medical Center Haaglanden, Erasmus Medical Center, Leiden University Medical Center, The Elisabeth-TweeSteden Hospital
Leads: UMC Utrecht